Advertisement
New Zealand markets closed
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5965
    +0.0028 (+0.47%)
     
  • NZD/EUR

    0.5558
    +0.0012 (+0.21%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    82.98
    +0.17 (+0.21%)
     
  • GOLD

    2,341.50
    +3.10 (+0.13%)
     
  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     
  • FTSE

    8,091.82
    +51.44 (+0.64%)
     
  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     
  • DAX

    17,958.77
    -129.93 (-0.72%)
     
  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • NZD/JPY

    92.7250
    +0.6100 (+0.66%)
     

Could This Be Moderna's Ticket to Long-Term Success?

Moderna (NASDAQ: MRNA) waited a long time to reach this important moment: the authorization of its vaccine in infants and children. This month, the FDA authorized the vaccine for both teens and children ages six months and older, and vaccine rollout has begun for the youngest group. Could this new authorization be Moderna's ticket to long-term success?